drugset / Trial / NCT00428077

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

NCT00428077

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase chronic myelogenous leukemia.

Timeline

Start
2005-10
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BCR-ABL junction-specific peptide vaccine Vaccine Subcutaneous
Background incomplete Freund's adjuvant Other / unclassified

Indications